CHAMPIONS ONCOLOGY, INC. 8-K

What Happened
Champions Oncology, Inc. (CSBR) filed an 8-K reporting that on March 24, 2026 the Board accepted the resignation of Dr. Philip Breitfeld and appointed Dr. Brian Alexander as a director to fill the vacancy. The filing states Dr. Breitfeld’s resignation was not due to any disagreement with the company. There are no arrangements, related-party transactions, or material contracts associated with Dr. Alexander’s appointment.

Key Details

• Resignation and appointment effective March 24, 2026: Dr. Philip Breitfeld resigned; Dr. Brian Alexander was appointed to the Board.
• No disagreement: Company confirms resignation not due to any disagreement over operations, policies, or practices.
• No reportable related-party transactions or special arrangements for Dr. Alexander per Item 404(a) of Regulation S-K.
• Dr. Alexander’s background: CEO of Valo Health (since Nov 2024), CEO-Partner at Flagship Pioneering (since Nov 2024), former SVP R&D at Roche/Genentech (Nov 2023–Nov 2024), former CEO and other roles at Foundation Medicine (2018–Nov 2023); medical and public health degrees (MD, MPH) and prior roles in academia and government (White House Fellow).

Why It Matters
Board composition changes are governance events investors watch because directors influence oversight and strategic direction. Dr. Alexander brings senior industry experience in pharmaceuticals, diagnostics, AI/data-driven drug development, and regulatory science—skills that may be relevant to Champions Oncology’s business and strategy. The filing notes there are no conflicts or special arrangements tied to his appointment, which reduces immediate governance or disclosure concerns.